Short Interest in iSpecimen Inc. (NASDAQ:ISPC) Increases By 272.6%

iSpecimen Inc. (NASDAQ:ISPC) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 1,136,955 shares, a growth of 272.6% from the December 15th total of 305,108 shares. Based on an average trading volume of 3,720,147 shares, the short-interest ratio is presently 0.3 days. Approximately 13.3% of the shares of the company are short sold. Approximately 13.3% of the shares of the company are short sold. Based on an average trading volume of 3,720,147 shares, the short-interest ratio is presently 0.3 days.

iSpecimen Trading Up 13.4%

Shares of ISPC traded up $0.04 during midday trading on Tuesday, reaching $0.35. The stock had a trading volume of 1,855,892 shares, compared to its average volume of 1,025,187. The company has a market capitalization of $3.43 million, a price-to-earnings ratio of -0.04 and a beta of 1.83. The company’s 50-day moving average is $0.45 and its 200 day moving average is $0.86. iSpecimen has a 12-month low of $0.26 and a 12-month high of $3.38.

iSpecimen (NASDAQ:ISPC) last posted its quarterly earnings results on Monday, November 17th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($3.80) by $3.32. The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $3.33 million. iSpecimen had a negative net margin of 343.86% and a negative return on equity of 531.78%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in iSpecimen stock. Scientech Research LLC acquired a new position in iSpecimen Inc. (NASDAQ:ISPC) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned 0.30% of iSpecimen at the end of the most recent reporting period. Institutional investors and hedge funds own 13.62% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of iSpecimen in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.